Close Menu

CHMP

Zykadia received conditional marketing authorization as a treatment for advanced NSCLC patients who've previously received the ALK inhibitor Xalkori, and so are known to be ALK positive.

Originally published Jan. 18.
EU's Committee for Medicinal Products for Human Use this week recommended that the European Medicine's Agency grant conditional marketing authorization for Pfizer's leukemia drug bosutinib.

The European Commission has granted conditional marketing authorization to Pfizer's Xalkori (crizotinib), a personalized treatment for non-small cell lung cancer.

Originally published Jan. 30.
The European Medicines Agency is seeking stakeholder input on how best to use pharmacogenomics data to advance personalized medicines.

The European Commission's Committee for Medicinal Products for Human Use last eek recommended marketing authorization for Roche's Zelboraf as a monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.

A Finnish government task force plans to release its final report on Aug. 31 after conducting further investigations into the epidemiologic, immunologic, and genetic causes for the onset of narcolepsy following vaccination with Pandemrix.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.